


# Current Adjuvant Therapy for Colorectal Cancer

John L. Marshall, MD  
 Chief, Division Hematology and Oncology  
 Director, Developmental Therapeutics and GI Oncology  
 Lombardi Cancer Center  
 Georgetown University



## The view from 35,000 feet



Everything looks the same from up here



## Adjuvant therapy for colon cancer **fails** 95% of the time in stage II colon cancer



Quasar Lancet. 2000 May 6;355(9215):1588-96

## X-ACT: Capecitabine vs Bolus 5-FU/LV (Mayo Clinic Regimen) for Dukes' C Colon Cancer<sup>1</sup>







Dukes' C colon cancer  
 Chemotherapy naïve  
 Resection ≤8 weeks  
 (N=1987)

Capecitabine 1250 mg/m<sup>2</sup> po bid,  
 days 1-14, every 3 weeks, x 8 cycles

5-FU 425 mg/m<sup>2</sup>, LV 20 mg/m<sup>2</sup> via bolus  
 IV infusion, days 1-5, every 28 days,  
 x 6 cycles (Mayo Clinic regimen)


- Trial powered to establish at least equivalence of Capecitabine to 5-FU/LV
- Primary endpoint: DFS
- Secondary endpoints included: OS and safety

X-ACT = XELODA in Adjuvant Colon Cancer Therapy.  
 1. Twelves C, et al. *N Engl J Med*. 2005;352:2696-2704.




## Do you believe in subsets or don't you?

- Why is 102 an adequate number to change standard of care and 63 is not?



## Why did irinotecan NOT work in the adjuvant setting?




Saltz, L. B. et al. J Clin Oncol; 25:3456-3461 2007


## Benefit of FOLFOX4 vs Control

Goldberg, R. M. et al. J Clin Oncol; 24:4085-4091 2006

< 70



≥ 70



Copyright © American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

## Do you believe in subsets or don't you?

- What would you give to a:
  - T2N0 (0 of 7 nodes positive)
  - T3N0 (0 of 30 nodes, poorly differentiated)
  - T2N1 (1 of 30 nodes positive, 75 y/o)
  - T3N1 (1 of 30 nodes positive, MSI-H)

I am so confused


## What we need to know:

- Who has microscopic disease
- Will treatment help
- If so, what treatment
- Does anatomic stage matter

We need to be careful with our conclusions

**Critical: Postsurgical ischemia**

pmTOR-immunostaining (Ventana)



**Do you believe in subsets or don't you?**

- What would you give to a:
  - T2N0 (0 of 7 nodes positive)
    - A pat on the back
  - T3N0 (0 of 30 nodes, poorly differentiated)
    - Would check genes, MSI
  - T2N1 (1 of 30 nodes positive, 75 y/o)
    - 5FU/LV
  - T3N1 (1 of 30 nodes positive, MSI-H)
    - FOLFOX

**NSABP C-08**

